A Pre-AGI AI startup just earned a mandate to take small-molecule cancer drug candidates all the way to preclinical — with patent rights in scope.
TL;DR: VIDRAFT, a Korean AI drug-discovery startup, has been selected for the South Korean Ministry of SMEs and Startups' 2026 "Everyone's Challenge Bio" public-private open-innovation program. The company will use its AI platform to discover and design small-molecule anticancer drug candidates and advance them toward preclinical development. VIDRAFT aims to secure intellectual property rights over any resulting drug compounds, backed by government funding and support from participating pharmaceutical companies.
VIDRAFT — the Korean Pre-AGI AI company focused on designing, producing, and validating AI models for industry — was officially chosen for the South Korean government's "Everyone's Challenge Bio" (모두의 챌린지 바이오) initiative in September 2026, marking a significant step in the company's transition from open research platform to commercial drug development.
VIDRAFT was selected as a final participant in the 2026 Public-Private Cooperative Open Innovation Support Program, administered under the Ministry of SMEs and Startups, following a multi-stage evaluation process that included document screening, a meetup, and a formal presentation assessment. The selection result was confirmed by the Chungbuk Creative Economy Innovation Center's program operations committee on September 4, 2026.
The program matches early-stage technology companies with pharmaceutical firms that have submitted specific, real-world research needs. Seventeen pharmaceutical companies joined the initiative as demand-side partners, including some of South Korea's most recognized names in the industry: Dong-A ST, Yuhan Corporation, Hanmi Pharmaceutical, SK Chemicals, and HK inno.N. The Korea Innovative Medicine Consortium (KIMCo) serves as a collaborator, and the Korea Startup Agency (KISED) acts as the designated specialist institution.
VIDRAFT's assigned project centers on small-molecule compound-based anticancer drug discovery. Using its AI capabilities, the company will identify and design drug candidates, subject them to computation-based validation, and then work toward linking the results to preclinical development milestones — all in accordance with output standards agreed upon with the participating pharmaceutical partners. The research will be funded through a combination of government grants and pharmaceutical company support. Securing intellectual property rights over any promising drug substances discovered during the project is an explicit goal.
Specific targets, experimental scope, and stage-by-stage responsibilities between VIDRAFT and its pharma partners will be defined in a jointly agreed implementation plan. The company will next complete a formal pledge and submit a revised project plan before finalizing a cooperative agreement.
At the center of VIDRAFT's drug discovery workflow is PharmaOS, its proprietary pharmaceutical research platform. PharmaOS supports molecular structure exploration, target protein binding analysis, and computation-based assessment of drug-likeness and toxicity risk. The platform's design philosophy prioritizes generating well-reasoned justifications for advancing specific candidates — not just producing large numbers of them. PharmaOS has previously published top rankings across 16 categories on Polaris, a globally recognized drug prediction benchmark.
VIDRAFT's broader research architecture layers additional tools on top of PharmaOS. Its quantum computing software, QuantumOS, is being explored to add quantum-classical hybrid computation for deeper molecular-level analysis. A separate system called CELLOS — currently under active development — models biological responses including cellular metabolism and inter-organ interactions, going beyond simple target-binding probability to generate hypotheses relevant to candidate comparison and downstream experimental design. Together, these systems are intended to form an automated, iterative discovery-and-validation loop where information from each stage feeds back into the next round of molecular design.
VIDRAFT also operates an open drug discovery platform called the Open Discovery Challenge (ODC) on Hugging Face, available in both Korean and English. Participants submit AI-designed molecules for computation-based scoring according to publicly defined criteria each season. As of September 6, 2026, a cumulative total of 13,067 submissions had been scored across four completed disease seasons — malaria, tuberculosis, Chagas disease, and non-opioid pain relief.
CEO Kim Min-sik commented that the scoring discipline built through the ODC — evaluating over 13,000 candidates against a consistent standard — has sharpened VIDRAFT's discovery and assessment framework. He stated that the company intends to demonstrate what that framework can produce when applied to an actual research problem posed by South Korea's leading pharmaceutical companies, with the goal of delivering results from candidate discovery all the way through to compound IP.
Being chosen through a competitive, demand-driven evaluation — rather than through direct sales outreach — means VIDRAFT's technology has been validated against real pharmaceutical research problems set by industry. The structure of the program also means VIDRAFT is not simply providing a software service; it is a co-investor in outcomes, with IP acquisition built into the project's stated goals. For a startup, that shift from platform provider to drug IP holder represents a meaningful expansion of its potential business model. The involvement of 17 major domestic pharma companies as demand partners also signals that AI-driven small-molecule discovery is increasingly viewed as production-ready infrastructure by Korean industry, not just an experimental curiosity.
Q: What is VIDRAFT's role in the "Everyone's Challenge Bio" program?
A: VIDRAFT will use its AI drug-discovery platform to identify and design small-molecule anticancer drug candidates, validate them through computation-based methods, and advance the results toward preclinical development, while pursuing IP rights over any discovered compounds.
Q: Which pharmaceutical companies are involved in the program alongside VIDRAFT?
A: Seventeen pharmaceutical companies joined as demand partners, including Dong-A ST, Yuhan Corporation, Hanmi Pharmaceutical, SK Chemicals, and HK inno.N.
Q: What is the Open Discovery Challenge (ODC) and how does it relate to this announcement?
A: ODC is VIDRAFT's publicly accessible molecular submission and scoring platform hosted on Hugging Face. It has logged 13,067 scored submissions across four disease seasons, and the evaluation rigor developed through ODC directly informs the methodology VIDRAFT will apply to the anticancer drug project.
Source: 바이오타임즈 (2026-09-07) — original article